DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
SONESITATUG VEDOTIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SONESITATUG VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OSOCIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Coagulation factor XI negative allosteric modulator
OSOCIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
EK5V9UL3WL
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOZISTOBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MOZISTOBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Ig epsilon chain C region inhibitor
TALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
9591BL735Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IDEC-159
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Tumor-associated antigen 72 inhibitor
IDEC-159
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BULUMTATUG FUVEDOTIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BULUMTATUG FUVEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLEMBATUMUMAB VEDOTIN
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Squamous Cell; Breast Neoplasms; Melanoma; Osteosarcoma
Transmembrane glycoprotein NMB binding agent
GLEMBATUMUMAB VEDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
1568H6A58U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CINPANEMAB
2
Antibody
Investigational
Unknown
Unknown
Parkinson Disease
Alpha-synuclein inhibitor
CINPANEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
W83JGQ40XX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAL
2
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; HIV Infections
Parathyroid hormone-related protein inhibitor
CAL
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUVEMCITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
SUVEMCITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REGN1033
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
REGN1033
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
XENTUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms; Breast Neoplasms
Insulin-like growth factor II inhibitor
XENTUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
X86Z1O656G
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TECOTABART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TECOTABART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EBRASODEBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
EBRASODEBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PASCOLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Tuberculosis
Interleukin-4 inhibitor
PASCOLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
N1IOA09R6A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-1512
2
Antibody
Investigational
Unknown
Unknown
Unknown
P-selectin inhibitor
RG-1512
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRAXIVITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TRAXIVITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VORSETUZUMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
VORSETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IODINE (131I) METUXIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IODINE (131I) METUXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONCOLYSIN M
2
Antibody
Investigational
Unknown
Unknown
Unknown
Myeloid cell surface antigen CD33 binding agent
ONCOLYSIN M
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INDEMAKITUG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
INDEMAKITUG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIRINKIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BIRINKIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CL-184
2
Antibody
Investigational
Unknown
Unknown
Unknown
Glycoprotein inhibitor
CL-184
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ICHORCUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Thrombin inhibitor
ICHORCUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
UW0H6X9FSQ
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MECBOTAMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MECBOTAMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MICVOTABART PELIDOTIN
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MICVOTABART PELIDOTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DAVUTAMIG
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
DAVUTAMIG
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REFLOCIBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
REFLOCIBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PLONMARLIMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Severe Acute Respiratory Syndrome
Unknown
PLONMARLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOVETUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Glioblastoma
Platelet-derived growth factor receptor alpha inhibitor
TOVETUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
2XY62K75UV
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOSEROLIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
BOSEROLIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PARIDIPRUBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
PARIDIPRUBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANUMIGILIMAB
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
ANUMIGILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INDENEBART
2
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
INDENEBART
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TREVOGRUMAB
2
Antibody
Investigational
Unknown
Unknown
Myositis, Inclusion Body; Sarcopenia
Growth/differentiation factor 8 inhibitor
TREVOGRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
87T4327873
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
28
29
30
31
32
33
34
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA